Impact of cardiovascular comorbidity on ovarian cancer mortality

Eileen H. Shinn, Daniel J. Lenihan, Diana L. Urbauer, Karen M. Basen-Engquist, Alan Valentine, Laura Palmero, Myrshia L. Woods, Pooja Patel, Alpa M. Nick, Mian M K Shahzad, Rebecca L. Stone, Antoinette Golden, Emma Atkinson, Susan K. Lutgendorf, Anil K. Sood

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: A retrospective cohort study utilizing prospectively collected data was conducted from August 2003 until March 2008 at M.D. Anderson Cancer Center. It is unknown whether cardiovascular comorbidity and chronic stress impact ovarian cancer outcome, which remains poor despite advances in therapy. The purpose of this study was to determine whether cardiovascular disease and markers that may be associated with stress are also associated with survival in patients with ovarian cancer. Methods: Participants with newly diagnosed epithelial ovarian cancer were followed until time of death or truncation of study period (median follow-up = 4.2 years; n = 271). Tumor characteristics (stage, tumor grade, histology, debulking status), demographic variables, and cardiovascular comorbidity were documented and compared to overall survival. Results: Of the nine cardiovascular events tracked during follow-up, venous thromboembolism [VTE; HR, 3.2; 95% confidence interval (CI), 1.8-5.5] and pulmonary hypertension (HR, 8.5; 95% CI, 3.9-18.7) were associated with shorter survival in multivariate analysis. In addition, high tumor grade, suboptimal cytoreduction, and baseline heart rate (HR, 1.02; 95% CI, 1.01-1.04) were related to decreased survival. Conclusion: Careful management of certain cardiovascular comorbidities may extend survival in patients with ovarian cancer. Our findings suggest that increased baseline heart rate and the development of VTE and pulmonary hypertension after cancer diagnosis may be significant predictors of survival in women with ovarian cancer. Impact: Our study emphasizes the importance of identifying and optimally treating tachycardia, VTE, and pulmonary hypertension in conjunction with cancer therapy.

Original languageEnglish (US)
Pages (from-to)2102-2109
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume22
Issue number11
DOIs
StatePublished - Nov 2013

Fingerprint

Ovarian Neoplasms
Comorbidity
Survival
Mortality
Pulmonary Hypertension
Neoplasms
Confidence Intervals
Heart Rate
Venous Thromboembolism
Tachycardia
Histology
Cohort Studies
Cardiovascular Diseases
Multivariate Analysis
Retrospective Studies
Demography
Therapeutics

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Shinn, E. H., Lenihan, D. J., Urbauer, D. L., Basen-Engquist, K. M., Valentine, A., Palmero, L., ... Sood, A. K. (2013). Impact of cardiovascular comorbidity on ovarian cancer mortality. Cancer Epidemiology Biomarkers and Prevention, 22(11), 2102-2109. https://doi.org/10.1158/1055-9965.EPI-13-0625

Impact of cardiovascular comorbidity on ovarian cancer mortality. / Shinn, Eileen H.; Lenihan, Daniel J.; Urbauer, Diana L.; Basen-Engquist, Karen M.; Valentine, Alan; Palmero, Laura; Woods, Myrshia L.; Patel, Pooja; Nick, Alpa M.; Shahzad, Mian M K; Stone, Rebecca L.; Golden, Antoinette; Atkinson, Emma; Lutgendorf, Susan K.; Sood, Anil K.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 22, No. 11, 11.2013, p. 2102-2109.

Research output: Contribution to journalArticle

Shinn, EH, Lenihan, DJ, Urbauer, DL, Basen-Engquist, KM, Valentine, A, Palmero, L, Woods, ML, Patel, P, Nick, AM, Shahzad, MMK, Stone, RL, Golden, A, Atkinson, E, Lutgendorf, SK & Sood, AK 2013, 'Impact of cardiovascular comorbidity on ovarian cancer mortality', Cancer Epidemiology Biomarkers and Prevention, vol. 22, no. 11, pp. 2102-2109. https://doi.org/10.1158/1055-9965.EPI-13-0625
Shinn EH, Lenihan DJ, Urbauer DL, Basen-Engquist KM, Valentine A, Palmero L et al. Impact of cardiovascular comorbidity on ovarian cancer mortality. Cancer Epidemiology Biomarkers and Prevention. 2013 Nov;22(11):2102-2109. https://doi.org/10.1158/1055-9965.EPI-13-0625
Shinn, Eileen H. ; Lenihan, Daniel J. ; Urbauer, Diana L. ; Basen-Engquist, Karen M. ; Valentine, Alan ; Palmero, Laura ; Woods, Myrshia L. ; Patel, Pooja ; Nick, Alpa M. ; Shahzad, Mian M K ; Stone, Rebecca L. ; Golden, Antoinette ; Atkinson, Emma ; Lutgendorf, Susan K. ; Sood, Anil K. / Impact of cardiovascular comorbidity on ovarian cancer mortality. In: Cancer Epidemiology Biomarkers and Prevention. 2013 ; Vol. 22, No. 11. pp. 2102-2109.
@article{3fa2581fbf6949d3b082ad5cd21c4ebd,
title = "Impact of cardiovascular comorbidity on ovarian cancer mortality",
abstract = "Background: A retrospective cohort study utilizing prospectively collected data was conducted from August 2003 until March 2008 at M.D. Anderson Cancer Center. It is unknown whether cardiovascular comorbidity and chronic stress impact ovarian cancer outcome, which remains poor despite advances in therapy. The purpose of this study was to determine whether cardiovascular disease and markers that may be associated with stress are also associated with survival in patients with ovarian cancer. Methods: Participants with newly diagnosed epithelial ovarian cancer were followed until time of death or truncation of study period (median follow-up = 4.2 years; n = 271). Tumor characteristics (stage, tumor grade, histology, debulking status), demographic variables, and cardiovascular comorbidity were documented and compared to overall survival. Results: Of the nine cardiovascular events tracked during follow-up, venous thromboembolism [VTE; HR, 3.2; 95{\%} confidence interval (CI), 1.8-5.5] and pulmonary hypertension (HR, 8.5; 95{\%} CI, 3.9-18.7) were associated with shorter survival in multivariate analysis. In addition, high tumor grade, suboptimal cytoreduction, and baseline heart rate (HR, 1.02; 95{\%} CI, 1.01-1.04) were related to decreased survival. Conclusion: Careful management of certain cardiovascular comorbidities may extend survival in patients with ovarian cancer. Our findings suggest that increased baseline heart rate and the development of VTE and pulmonary hypertension after cancer diagnosis may be significant predictors of survival in women with ovarian cancer. Impact: Our study emphasizes the importance of identifying and optimally treating tachycardia, VTE, and pulmonary hypertension in conjunction with cancer therapy.",
author = "Shinn, {Eileen H.} and Lenihan, {Daniel J.} and Urbauer, {Diana L.} and Basen-Engquist, {Karen M.} and Alan Valentine and Laura Palmero and Woods, {Myrshia L.} and Pooja Patel and Nick, {Alpa M.} and Shahzad, {Mian M K} and Stone, {Rebecca L.} and Antoinette Golden and Emma Atkinson and Lutgendorf, {Susan K.} and Sood, {Anil K.}",
year = "2013",
month = "11",
doi = "10.1158/1055-9965.EPI-13-0625",
language = "English (US)",
volume = "22",
pages = "2102--2109",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Impact of cardiovascular comorbidity on ovarian cancer mortality

AU - Shinn, Eileen H.

AU - Lenihan, Daniel J.

AU - Urbauer, Diana L.

AU - Basen-Engquist, Karen M.

AU - Valentine, Alan

AU - Palmero, Laura

AU - Woods, Myrshia L.

AU - Patel, Pooja

AU - Nick, Alpa M.

AU - Shahzad, Mian M K

AU - Stone, Rebecca L.

AU - Golden, Antoinette

AU - Atkinson, Emma

AU - Lutgendorf, Susan K.

AU - Sood, Anil K.

PY - 2013/11

Y1 - 2013/11

N2 - Background: A retrospective cohort study utilizing prospectively collected data was conducted from August 2003 until March 2008 at M.D. Anderson Cancer Center. It is unknown whether cardiovascular comorbidity and chronic stress impact ovarian cancer outcome, which remains poor despite advances in therapy. The purpose of this study was to determine whether cardiovascular disease and markers that may be associated with stress are also associated with survival in patients with ovarian cancer. Methods: Participants with newly diagnosed epithelial ovarian cancer were followed until time of death or truncation of study period (median follow-up = 4.2 years; n = 271). Tumor characteristics (stage, tumor grade, histology, debulking status), demographic variables, and cardiovascular comorbidity were documented and compared to overall survival. Results: Of the nine cardiovascular events tracked during follow-up, venous thromboembolism [VTE; HR, 3.2; 95% confidence interval (CI), 1.8-5.5] and pulmonary hypertension (HR, 8.5; 95% CI, 3.9-18.7) were associated with shorter survival in multivariate analysis. In addition, high tumor grade, suboptimal cytoreduction, and baseline heart rate (HR, 1.02; 95% CI, 1.01-1.04) were related to decreased survival. Conclusion: Careful management of certain cardiovascular comorbidities may extend survival in patients with ovarian cancer. Our findings suggest that increased baseline heart rate and the development of VTE and pulmonary hypertension after cancer diagnosis may be significant predictors of survival in women with ovarian cancer. Impact: Our study emphasizes the importance of identifying and optimally treating tachycardia, VTE, and pulmonary hypertension in conjunction with cancer therapy.

AB - Background: A retrospective cohort study utilizing prospectively collected data was conducted from August 2003 until March 2008 at M.D. Anderson Cancer Center. It is unknown whether cardiovascular comorbidity and chronic stress impact ovarian cancer outcome, which remains poor despite advances in therapy. The purpose of this study was to determine whether cardiovascular disease and markers that may be associated with stress are also associated with survival in patients with ovarian cancer. Methods: Participants with newly diagnosed epithelial ovarian cancer were followed until time of death or truncation of study period (median follow-up = 4.2 years; n = 271). Tumor characteristics (stage, tumor grade, histology, debulking status), demographic variables, and cardiovascular comorbidity were documented and compared to overall survival. Results: Of the nine cardiovascular events tracked during follow-up, venous thromboembolism [VTE; HR, 3.2; 95% confidence interval (CI), 1.8-5.5] and pulmonary hypertension (HR, 8.5; 95% CI, 3.9-18.7) were associated with shorter survival in multivariate analysis. In addition, high tumor grade, suboptimal cytoreduction, and baseline heart rate (HR, 1.02; 95% CI, 1.01-1.04) were related to decreased survival. Conclusion: Careful management of certain cardiovascular comorbidities may extend survival in patients with ovarian cancer. Our findings suggest that increased baseline heart rate and the development of VTE and pulmonary hypertension after cancer diagnosis may be significant predictors of survival in women with ovarian cancer. Impact: Our study emphasizes the importance of identifying and optimally treating tachycardia, VTE, and pulmonary hypertension in conjunction with cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84887304575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887304575&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-13-0625

DO - 10.1158/1055-9965.EPI-13-0625

M3 - Article

C2 - 24045927

AN - SCOPUS:84887304575

VL - 22

SP - 2102

EP - 2109

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 11

ER -